Status:
COMPLETED
Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Conditions:
Peritoneal Mesotheliomas
Eligibility:
All Genders
Brief Summary
Review of the investigators hospital experience in cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) for peritoneal mesotheliomas, using Oxaliplatin as intraperitoneal chemo...
Detailed Description
Observation of primary outcome: * Overall Survival * Disease-free survival Influencing factors that will be observe: * Sex * Blood loss * Time of surgery * Number of resection and anastomosis * Per...
Eligibility Criteria
Inclusion
- Peritoneal mesothelioma
Exclusion
- Non resectable disease
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT01812148
Start Date
January 1 2012
End Date
March 1 2013
Last Update
March 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maisonneuve Rosemont Hospital
Montreal, Quebec, Canada, H1T 2M4